Corbion Reports Exciting Financial Results for 2024
Corbion, a pioneering company listed in Amsterdam, is dedicated to sustainable ingredient solutions that enhance preservation through innovative science. The company has recently shared its results for the first nine months of the fiscal year.
Key Highlights of the First Nine Months
The first nine months of the year were noteworthy, showcasing some impressive achievements:
- Organic Sales Growth: Increased by 2.6% with Q3 showing an outstanding 9.2% growth.
- Volume/Mix Improvements: A notable rise of 6.1% during the period and 11.1% in Q3.
- Pricing Adjustments: A reduction in prices by 3.5% year-to-date and -1.9% in Q3.
Operational Performance Metrics
Corbion's operations exhibit robust figures:
- Sales: Reached €972.9 million for the year so far, with Q3 accounting for €335.8 million.
- Adjusted EBITDA: Totaled €135.7 million, with €49.6 million in Q3.
- Operating Profit: Recorded a growth of €62.1 million in total, with Q3 profits at €28.5 million.
Free Cash Flow and EBITDA Growth
The company reported a strong free cash flow of €302.1 million. When excluding divestment proceeds, this amount stands at €50.8 million. The double-digit growth trajectory in sales and Adjusted EBITDA, especially within the Health & Nutrition sector, showcases Corbion's potential for future expansion.
Functional Ingredients and Solutions
In the realm of Functional Ingredients & Solutions, Corbion continues to see promising growth in volume and mix. Despite some challenges in the biochemicals market, their Food segment has performed particularly well. They also experienced robust sales growth, primarily in their Health & Nutrition segment.
Upgraded Full-Year Guidance for 2024
Corbion has raised its outlook for the fiscal year 2024, reflecting confidence in ongoing operations:
- Volume/Mix Growth: Expectations have increased to more than 5%, previously estimated at 2 - 6%.
- Adjusted EBITDA Growth: Predictions now stand at 22 - 25%, compared to the prior guidance of over 18%.
- Free Cash Flow Outlook: Estimated to exceed €60 million, an upgrade from the previous mark of over €50 million.
CEO Remarks on Company Performance
Olivier Rigaud, CEO of Corbion, expressed satisfaction regarding the company's solid performance, emphasizing the stability and resilience of their business model. The advancements made in their restructuring program have greatly contributed to improved margins.
Continued Development in Key Areas
Corbion is witnessing sustained momentum in its Health & Nutrition vertical. The Nutrition segment, notably in Omega-3 DHA for aquaculture and pet nutrition, is a major driver of success. Additionally, double-digit growth has been reported across all segments, including Nutrition, Biomedical polymers, and Pharma during Q3.
New Developments in Production
Moreover, the launch of their new circular lactic acid plant in Thailand is proceeding well. The lactic acid produced is already being delivered to a joint venture for the production of PLA, further enhancing Corbion's position in the market.
Frequently Asked Questions
1. What has been the organic sales growth for Corbion in 2024?
Corbion achieved an organic sales growth of 2.6%, with a substantial increase of 9.2% in Q3 2024.
2. How is Corbion performing in terms of free cash flow?
The company reported a free cash flow of €302.1 million, which stands at €50.8 million excluding divestment proceeds.
3. What adjustments have been made to Corbion's full-year guidance?
Corbion has upgraded its full-year guidance for 2024, anticipating volume/mix growth exceeding 5% and Adjusted EBITDA growth of 22 - 25%.
4. What areas is Corbion experiencing growth in?
Strong growth is observed in the Health & Nutrition sector along with positive momentum in Functional Ingredients & Solutions.
5. What developments are taking place with Corbion's new plant in Thailand?
The circular lactic acid plant in Thailand has successfully started production and is supplying lactic acid for PLA production through a joint venture.
